Both are once-weekly incretin agonists approved for type 2 diabetes and obesity — but different receptor targets, trial outcomes, and synthesis profiles distinguish them. This page covers what the research actually shows.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | Semaglutide | Tirzepatide |
|---|---|---|
| Generic name | Semaglutide | Tirzepatide |
| Brand names | Ozempic · Wegovy · Rybelsus | Mounjaro · Zepbound |
| Developer | Novo Nordisk | Eli Lilly |
| Receptor targets | GLP-1R only | GIP-R + GLP-1R |
| Agonism class | Mono-agonist | Dual-agonist ("twincretin") |
| Chain length | 31 amino acids | 39 amino acids |
| Half-life | ~168 h (once-weekly) | ~120 h (once-weekly) |
| Approved: T2D | Yes (2017, Ozempic) | Yes (2022, Mounjaro) |
| Approved: obesity | Yes (2021, Wegovy) | Yes (2023, Zepbound) |
| Peak weight ↓ (pivotal trial) | ~15% (STEP-1, sema 2.4 mg) | ~22% (SURMOUNT-1, tirz 15 mg) |
| Head-to-head weight ↓ | ~13% (SURMOUNT-5) | ~21% (SURMOUNT-5) |
| CV outcome trial | SELECT (MACE reduction confirmed) | SURPASS-CVOT (non-inferior vs sema) |
The mechanism difference is the reason tirzepatide produces greater weight loss
GLP-1R agonism (shared)
GIP-R agonism (tirzepatide only)
The precise contribution of GIP-R agonism to tirzepatide’s weight-loss advantage is still being studied. Some analyses suggest GIP receptor potentiation of GLP-1 signaling; others point to independent adipose-tissue effects. The outcome data — tirzepatide outperforming semaglutide in head-to-head trials — is established; the mechanistic explanation remains an active research question.
Selected pivotal and head-to-head studies — population means, not individual predictions
−14.9% vs −2.4% (placebo)
Pivotal obesity trial for Wegovy
−22.5% vs −2.4% (placebo)
Pivotal obesity trial for Zepbound
~21% (tirz) vs ~13% (sema)
Direct head-to-head; tirzepatide superior on primary endpoint
20% MACE reduction vs placebo
Established CV benefit in obesity without T2D
Non-inferior; full results pending publication
T2D CV outcome trial; comparator is diabetes-dose sema (not Wegovy dose)
SURMOUNT-5 is the principal direct head-to-head weight-loss comparison; SURPASS-CVOT uses a diabetes-dose semaglutide comparator, not the 2.4 mg weight-management dose, so it is not a head-to-head weight-loss trial.
| Dimension | Semaglutide | Tirzepatide | Why it matters |
|---|---|---|---|
| Chain length | 31 AA | 39 AA | More residues = more coupling cycles = more deletion impurities to purify away |
| Acylation | C18 fatty-diacid on Lys34 via mini-PEG/γGlu linker | C20 fatty-diacid on Lys26 via modified linker | Both require post-chain solution-phase acylation steps |
| Receptor design | Native GLP-1 backbone with Aib substitutions | Chimeric GIP/GLP-1 sequence — custom pharmacophore | Tirz sequence is de novo designed; more complex orthogonal analytical work needed |
| Purity requirement | Pharma-grade RP-HPLC + SEC + MS | Same, plus more complex impurity profile from longer chain | A credible COA is the minimum bar for any research-grade material of either compound |
Retatrutide — triple agonist (GIP/GLP-1/GcgR)
Adding glucagon-receptor agonism to the GIP/GLP-1 dual mechanism introduces a third signal: thermogenesis and increased energy expenditure via hepatic and peripheral GcgR. In Phase 2 trials, retatrutide reported approximately 24% mean body-weight reduction at 48 weeks — exceeding both semaglutide and tirzepatide data — though it remains investigational and has not received FDA approval.
Retatrutide catalog entryWhat is the main difference between semaglutide and tirzepatide?
Semaglutide activates only the GLP-1 receptor (mono-agonism). Tirzepatide simultaneously activates both the GIP and GLP-1 receptors (dual agonism). This additional GIP-receptor engagement is associated with larger body-weight reductions in both placebo-controlled and direct head-to-head trials.
Which produces more weight loss — semaglutide or tirzepatide?
In the SURMOUNT-5 direct head-to-head trial, tirzepatide 15 mg achieved approximately 21% mean body-weight reduction vs approximately 13% for semaglutide 2.4 mg over 72 weeks. The difference was statistically significant on the primary endpoint. Pivotal trials of each compound individually reported similar hierarchies: SURMOUNT-1 (tirzepatide, ~22.5%) vs STEP-1 (semaglutide, ~15%). Individual responses vary, and these are population means — not predictions for any individual.
Are Ozempic and Mounjaro the same as Wegovy and Zepbound?
Ozempic and Wegovy are both semaglutide but at different doses: Ozempic (≤2 mg) is approved for type 2 diabetes; Wegovy (2.4 mg) is approved for chronic weight management. Similarly, Mounjaro (≤15 mg) is tirzepatide for type 2 diabetes and Zepbound (≤15 mg) is tirzepatide for weight management. The active compound is the same in each pair; dose, labeling, and FDA indication differ.
Is tirzepatide FDA approved?
Yes. Tirzepatide is approved by the FDA as Mounjaro for type 2 diabetes (2022) and as Zepbound for chronic weight management (2023). Both are prescription-only medications.
What does GIP add to GLP-1 agonism?
GIP (glucose-dependent insulinotropic polypeptide) provides a complementary insulinotropic signal through GIPR receptors in the pancreas and potentially an adipose-tissue signal through peripheral GIPR. In tirzepatide, co-activation of both receptor types is hypothesized to produce synergistic satiety and metabolic effects that exceed GLP-1 agonism alone — supported by the magnitude of weight loss in trials.
How does retatrutide compare to both?
Retatrutide (LY3437943) adds glucagon-receptor (GcgR) agonism to the GIP/GLP-1 dual mechanism — making it a triple agonist. In Phase 2 trials, it reported approximately 24% mean body-weight reduction at the highest dose, exceeding both semaglutide and tirzepatide data. It remains investigational and has not received FDA approval.
Which compound is harder to synthesize?
Tirzepatide is the more demanding synthesis — its 39-residue chimeric sequence is longer than semaglutide's 31 residues, and the custom dual-receptor pharmacophore requires more complex analytical characterization. Both compounds require post-chain acylation, RP-HPLC purification, and mass-spectrometry identity confirmation. A credible certificate of analysis is essential for any research-grade material of either.